Treatment of advanced gastrointestinal stromal tumors in patients over 75 years old: clinical and pharmacological implications
- 21 December 2012
- journal article
- day to-day-practice
- Published by Springer Science and Business Media LLC in Targeted Oncology
- Vol. 8 (4), 295-300
- https://doi.org/10.1007/s11523-012-0243-8
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity TrialHaematologica, 2012
- Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis of 1,640 PatientsJournal of Clinical Oncology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Does a Geriatric Oncology Consultation Modify the Cancer Treatment Plan for Elderly Patients?The Journals of Gerontology: Series A, 2008
- Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033Journal of Clinical Oncology, 2008
- Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based studyBMC Cancer, 2007
- Gastrointestinal stromal tumourThe Lancet, 2007
- Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate eraCancer, 2005
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987